The Bio Report

One of the challenges in treating the neurodegenerative condition Alzheimer’s disease is intervening early enough in the course of illness to provide meaningful benefit. AltPep is developing therapeutics with companion diagnostics that target toxic α-sheet–containing oligomers, which are thought to form very early in the disease and act as molecular triggers of downstream amyloid pathology. These structures are believed to represent some of the earliest detectable stages of Alzheimer’s and to promote the formation of amyloid plaques, a hallmark feature of the condition.​ We spoke with Valerie Daggett, founder and CEO of AltPep, about the relationship between α-sheet oligomers and the onset of Alzheimer’s disease, how the company’s synthetic peptides are designed to bind and neutralize these pathogenic agents, and the potential for this platform to be extended to a broader set of amyloid diseases.

Biotech stocks staged a dramatic turnaround in 2025, with the XBI well outpacing the S&P 500 despite concerns over leadership changes at the U.S. Food and Drug Administration, the Trump administration’s efforts to put constraints on drug pricing, and its broader cuts to health and science agencies. A pick-up in deal-making, along with falling interest rates, helped buoy the sector with growing anticipation for continued improvement in 2026. We sat down with Adam Feuerstein, senior biotech writer for STAT, for our annual review-preview edition, the noteworthy trends in the biotech sector 2025, and what’s in store at the upcoming JPMorgan Healthcare Conference and beyond in 2026.   

The approach to post-surgical pain relief has relied on short-duration treatments and notably opioids. That’s led to the associated risks of dependence and abuse, prolonged hospitalizations, and slower recoveries. Allay Therapeutics is developing an alternative to opioids to treat post-surgical pain with an initial focus on knee replacement surgeries. Allay’s guitar pick-sized polymer is implanted during surgical procedures and it releases the analgesic bupivacaine as it dissolves over 30 days. We spoke to Adam Gridley, CEO of Allay Therapeutics, about post-surgical pain, the need for alternatives to opioids; and the company’s implanted, extended-release analgesic.

Physicians can learn a lot from talking to patients, and not just from the words they say, but from millions of data points from acoustic features of their speech, such as pitch, vocal cord vibration patterns, and micro-instabilities in the voice. Canary Speech has developed an AI-based diagnostic listening tool that can detect neurological and psychiatric conditions from physiological signals in the voice. We spoke to Kang Hsu, chief medical officer of Canary Speech, about how its diagnostic tool works, how it is embedded invisibly into clinical workflows, and how the company is driving physician adoption.

Sepsis remains one of medicine’s most intractable and costly problems, arising when an infection triggers a runaway immune response that damages organs long after a pathogen is controlled. It accounts for an estimated $53 billion in Medicare spending alone, yet more than a hundred drug trials have failed to yield a single approved drug that directly treats the underlying immune dysfunction. Inflam­matix, which grew out of work at Stanford University, has developed a point-of-care blood test to determine whether an infection is bacterial or viral, as well as the severity of the patient’s immune response to optimize treatment. We spoke to Tim Sweeney, CEO of Inflammatix, about the company’s TriVerity test for sepsis, how it works, and how it is used in an ER setting to determine who needs antibiotics, ICU‑level care, or a broader diagnostic workup.​